Q3 – Alligator Bioscience

2024-10-24

Regulatory

Alligator Bioscience AB reports financial results for the first 9 months of 2024 and for Q3 2024 and provides a business update

Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 ...

2023-10-26

Regulatory

European Medicines Agency grants mitazalimab Orphan Designation in pancreatic cancer Technical Feasibility achieved in second collaboration ...

2022-10-20

Patient enrolment for OPTIMIZE-1 Phase 2 study ahead of schedule with top-line data now brought forward to Q1 2024 and interim data on track ...

2021-10-21

Regulatory

First Patient Dosed in Optimize-1 Phase II “We continued to make great strides in the third quarter of 2021. The first patient was dosed in ...

2020-10-22

Regulatory

Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented ...

2019-10-24

Regulatory

"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 su ...

2018-10-26

Regulatory

The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator’s research and development. Significant even ...

2017-10-25

Regulatory

Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...